XTL Biopharmaceuticals Ltd. stock is down -3.41% since 30 days ago. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 52.63% of the previous 18 February’s closed higher than January.
The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. is headquartered in Ramat Gan, Israel.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!